FDA Clarifies Enrollment Standards for Geriatric Patients in Drug Development

By Cynthia Gomez

The Food and Drug Administration adopted guidance that pushes drug developers to include older adults in clinical trials. Officials advise against arbitrary age caps unless a scientific reason exists to exclude participants. This approach seeks to produce evidence that matches how medicines perform in the age group that relies on them most.

The standards date back to a 1994 ICH document. They line up with later policies from the NIH and EMA. Older adults take a large share of prescriptions, yet their data has often lagged behind.

What this means

Agency positions show a gap between who enrolls in studies and who ends up using the drugs. Many in this population live with multiple conditions and take several medications daily. Trial results that overlook these factors leave clinicians with incomplete pictures of safety and dosing needs in real patients.

Key takeaways

• Older adults consume a disproportionate share of medications yet have historically been excluded from trials on the basis of age, comorbidities, or concomitant medications. [1]
• Clinical trials should generate data relevant to the target population. Age-related physiologic changes, polypharmacy, and frailty must be considered in trial design. [1]
• Regulatory agencies (FDA, EMA) and research funders (NIH) support removal of arbitrary age caps and encourage stratified enrollment and targeted recruitment. [1][2][3]
• Pharmacokinetic and safety studies in older adults are particularly important because drug metabolism and adverse-event profiles can differ substantially from younger populations. [1]
• NIH policy requires inclusion of older adults. Exclusion by age must be scientifically justified. [2]

FDA and ICH standards

The FDA guidance recommends against upper age limits in protocols. Older adults should be included unless there is a specific scientific justification for exclusion. [1]

Guidance encourages enrollment across geriatric age strata. Sufficient numbers in the 65–74, 75–84, and 85 and older groups permit subgroup analysis of safety and efficacy. [3]

Studies must examine age-related pharmacokinetic differences. Protocols need to account for comorbidities and polypharmacy as well.

NIH requirements

The National Institutes of Health set its Inclusion Across the Lifespan policy in 2019. It applies to all NIH-funded human subjects research. Exclusion by age must carry scientific justification. [2]

International alignment

The European Medicines Agency follows the same ICH E7 (R1) framework. This creates consistent expectations among FDA, EMA and NIH on geriatric inclusion. [3]

All three sources stress the value of data generated in populations that reflect actual medication users.

FAQ

What are the key design and analysis recommendations for trials that include older adults?
Recommendations include enrollment of enough participants in the 65-74, 75-84 and 85-plus age bands to support subgroup analysis. Protocols should evaluate age effects on drug processing, comorbidities and use of multiple medications at once. [3]

Why have older adults historically been underrepresented in clinical research?
Sponsors have often excluded them because of age, additional health conditions or concurrent medications. This pattern persisted even though the group accounts for a large share of drug consumption. [1]

How do FDA, NIH, and EMA approaches align on geriatric trial inclusion?
The agencies align on avoiding unjustified age-based exclusions from trials. FDA and EMA reference the ICH E7 guidance directly. NIH policy requires consideration of older adults in all funded research. [1][2][3]

What practical steps can sponsors take to improve recruitment and retention of older participants?
Guidance documents note the value of trial designs with suitable endpoints and recruitment strategies for geriatric populations. These approaches factor in age-related changes and common health profiles. [1][3]

Limitations

Guidance documents are not legally binding. Actual inclusion rates still depend on sponsor decisions and operational feasibility. Heterogeneity within the older-adult population means additional tailored approaches may be needed beyond minimum regulatory expectations. Empirical evidence on post-guidance enrollment improvements is still emerging.